drugset / Trial / NCT05270733

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

NCT05270733

NaSingle-groupOpen-labelTreatment

Summary

The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive efficacy would lead to a more personalized approach for psoriasis treatment. To do this, the investigators will be asking participants to try two different already on the market FDA-approved psoriasis drugs for 8 weeks at a time. The investigators will be monitoring participants skin for improvements as well as taking blood and skin samples at least three times. Investigators may also ask to take stool samples and/or skin swabs.

Timeline

Start
2022-11-10
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody 100 mg Subcutaneous
Subject Risankizumab Monoclonal antibody 150 mg Subcutaneous
Subject Ustekinumab Monoclonal antibody 90 mg Subcutaneous

Indications